deucravacitinib


( Last Updated : January 3, 2023)
Generic Name:
deucravacitinib
Project Status:
Active
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
Bristol-Myers Squibb Company
Brand Name:
Sotyktu
Project Line:
Reimbursement Review
Project Number:
SR0756-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
‚ÄčThe treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openAugust 29, 2022
Call for patient/clinician input closedOctober 24, 2022
Clarification:

- Patient input submission received from the Canadian Psoriasis Network (CPN) and Canadian Association of Psoriasis Patients (CAPP)

Submission receivedSeptember 27, 2022
Submission acceptedOctober 12, 2022
Review initiatedOctober 13, 2022
Draft CADTH review report(s) provided to sponsor for commentJanuary 03, 2023
Deadline for sponsors commentsJanuary 12, 2023
CADTH review report(s) and responses to comments provided to sponsorFebruary 09, 2023
Expert committee meeting (initial)February 22, 2023
Draft recommendation issued to sponsorMarch 06, 2023
To
March 08, 2023
Draft recommendation posted for stakeholder feedbackMarch 16, 2023
End of feedback periodMarch 31, 2023